

1 **Brief Communication**

2

3 **Immune history shapes human antibody responses to H5N1**
4 **influenza viruses**

5

6

7 Tyler A. Garretson^{1,#}, Jiaojiao Liu^{1,#}, Shuk Hang Li^{1,#}, Gabrielle Scher^{1,#}, Jefferson J.S.
8 Santos^{1,#}, Glenn Hogan², Marcos Costa Vieira³, Colleen Furey¹, Reilly K. Atkinson¹,
9 Naiqing Ye¹, Jordan Ort¹, Kangchon Kim³, Kevin A. Hernandez¹, Theresa Eilola¹, David
10 C. Schultz⁴, Sara Cherry², Sarah Cobey³, Scott E. Hensley^{1,*}

11

12

13 ¹*Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,*
14 *Philadelphia, Pennsylvania*

15 ²*Department of Pathology, Perelman School of Medicine, University of Pennsylvania,*
16 *Philadelphia, Pennsylvania*

17 ³*Department of Ecology & Evolution, The University of Chicago, Chicago, IL*

18 ⁴*Department of Biochemistry & Biophysics, Perelman School of Medicine, University of*
19 *Pennsylvania, Philadelphia, Pennsylvania*

20

21

22

23

24

25

26

27 #these authors contributed equally

28 *corresponding author: 402 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA
29 19104. Phone: (215) 573-3756. Email: hensley@pennmedicine.upenn.edu

30

31 Running title: Human H5N1 antibody responses

32

33

34 **Abstract**

35 Avian H5N1 influenza viruses are circulating widely in cattle and other mammals and
36 pose a risk for a human pandemic. Previous studies suggest that older humans are
37 more resistant to H5N1 infections due to childhood imprinting with other group 1 viruses
38 (H1N1 and H2N2); however, the immunological basis for this is incompletely understood.
39 Here we show that antibody titers to historical and recent H5N1 strains are highest in
40 older individuals and correlate more strongly with year of birth than with age, consistent
41 with immune imprinting. After vaccination with an A/Vietnam/1203/2004 H5N1 vaccine,
42 both younger and older humans produced H5-reactive antibodies to the vaccine strain
43 and to a clade 2.3.4.4b isolate currently circulating in cattle, with higher seroconversion
44 rates in young children who had lower levels of antibodies before vaccination. These
45 studies suggest that younger individuals might benefit more from vaccination than older
46 individuals in the event of an H5N1 pandemic.

47

48 **Main text**

49 Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5 viruses began
50 circulating at high levels in bird populations across the world in 2020¹⁻⁴ and have caused
51 infections in mammals such as foxes, seals, and mink⁵⁻⁸. At the end of 2023, a clade
52 2.3.4.4b H5N1 virus began circulating in dairy cattle in the United States⁹, with
53 widespread transmission between cows¹⁰. Clade 2.3.4.4b H5N1 viruses do not currently
54 bind well to receptors found in human upper airways^{11,12}; however, widespread
55 circulation in mammals could lead to adaptive substitutions that increase viral
56 attachment, replication, and human transmission^{13,14}.

57 Previously circulating H5N1 viruses caused higher mortality rates in younger
58 humans relative to older humans^{15,16}. It is possible that immunity elicited by seasonal
59 influenza viruses affects H5N1 susceptibility. Influenza A viruses can be broadly split into
60 2 different phylogenetic groups¹⁷. Group 1 (H1N1 and H2N2) and group 2 (H3N2)
61 viruses have circulated during distinct times since 1918 (**Fig. 1a**), and therefore
62 immunity against each of these viruses is partly shaped by an individual's birth year
63 (**Extended Fig. 1**). Gostic and colleagues proposed that individuals born before 1968
64 may be more refractory to severe disease following H5N1 (a group 1 virus) infection
65 since most of these individuals were likely 'immunologically imprinted' with other group 1
66 viruses (H1N1 and H2N2) in childhood¹⁸. Although H5N1 is antigenically distinct from
67 H1N1 and H2N2, all three of these viruses share homology in conserved epitopes,
68 including the hemagglutinin (HA) stalk domain¹⁷. Previous studies reported that H1 stalk-
69 reactive antibodies are more prevalent in older individuals^{19,20}; however, a subsequent
70 study found no clear association with H1 stalk-reactive antibodies and birth year among
71 adults²¹.

72 We quantified antibodies reactive to group 1 HA stalks (H1 and H5) and group 2
73 HA stalks (H3 and H7) in serum samples collected in 2017 from 121 healthy adults born

74 between 1927-1998 (19-90 years old at time of sampling). H1 and H5 stalk-reactive
75 antibodies were higher in older adults, although younger adults possessed moderate
76 amounts of these antibodies (**Fig. 1b-c**). We asked if stalk-reactive antibody levels
77 correlated with the probability of immune imprinting (i.e., initial infection in childhood)
78 with viruses of the same subtype or group, estimated from historical data. H1 and H5
79 stalk-reactive antibody titers were both positively correlated with group 1 and H1N1
80 imprinting probabilities (**Table S1**). We found that group 2 HA stalk antibody levels were
81 generally lower with no obvious correlation between titer and birth year (**Fig. 1d-e, Table**
82 **S1**). H3 stalk-reactive antibodies were present in sera at similar levels regardless of
83 donor age (**Fig. 1d**) and H7 stalk-reactive antibodies were generally low in the sera from
84 most donors (**Fig. 1e**).

85 Consistent with the group 1 HA stalk titer data, we found that individuals
86 imprinted with group 1 viruses in childhood possessed high levels of antibodies reactive
87 to clade 1 H5 full length HA (A/Vietnam/1203/2004) (**Fig. 1f, Table S1**) and clade
88 2.3.4.4b H5 full length HAs (A/Pheasant/New York/22-00906-001/2022 and A/Dairy
89 Cattle/Texas/24-008749-002-v/2024) (**Fig. 1g, Extended Data Fig. 2, and Table S1**).
90 Most of these cross-reactive antibodies were non-neutralizing, although we detected
91 antibodies that neutralized clade 1 and clade 2.3.4.4b H5N1 in rare individuals of all
92 ages (**Extended Data Fig. 3**). Taken together, our data suggest that childhood
93 exposures to H1N1 and H2N2 prime mostly non-neutralizing group 1 HA stalk antibodies
94 that bind to diverse H5 HAs.

95 Previous studies showed that H5 vaccines elicit HA stalk antibodies in
96 humans^{22,23}; however, it is unknown if H5 vaccines elicit different levels of HA stalk
97 antibodies in individuals with different birth years. We obtained serum samples collected
98 from children and adults (born between 1918-2003) before and after administration of a
99 45 µg dose of an H5N1 (A/Vietnam/1203/2004) unadjuvanted vaccine (ClinicalTrials.gov

100 #s: NCT00133536, NCT00230750, NCT00115986²⁴). Since these clinical studies were
101 completed in the years 2005-2006, the participants ranged from 2-97 years of age at
102 time of vaccination. All participants received a prime-boost regimen, and we analyzed
103 serum samples before vaccination and 28 days after the 1st and 2nd vaccination.
104 Consistent with our previous results, older adults possessed high levels of H5 stalk-
105 reactive antibodies before vaccination (**Fig. 2a**). H5 stalk-reactive antibody levels
106 increased slightly in older individuals and more substantially in children after each
107 vaccination (**Fig. 2b-c**). We observed the highest fold change in H5 stalk-reactive
108 antibody titers in children, whose antibody levels were lower prior to vaccination (**Fig.**
109 **2d**). We obtained similar data when we measured antibodies reactive to the full length
110 A/Vietnam/1203/2004 HA vaccine antigen (**Fig. 2e-h**). Older individuals possessed
111 higher levels of A/Vietnam/1203/2004 HA-reactive antibodies relative to children before
112 vaccination (**Fig. 2e**) and these antibodies were boosted in participants in all age groups
113 after vaccination (**Fig. 2f-g**) with the greatest benefit in children (**Fig. 2h**). Consistent
114 with a recent report²⁵, we found that the clade 1 A/Vietnam/1203/2004 H5N1 vaccine
115 elicited antibodies that bound to the more recent antigenically distinct clade 2.3.4.4b HA
116 (**Fig. 2i-l**). Antibody levels against the clade 1 and clade 2.3.4.4b HAs were similar after
117 vaccination (compare **Fig. 2g** and **Fig. 2k**).

118 While some HA stalk antibodies are broadly neutralizing, many of these
119 antibodies protect through Fc receptor-dependent mechanisms such as antibody
120 dependent cellular cytotoxicity (ADCC)²⁶. We therefore determined if antibodies elicited
121 by the A/Vietnam1203/2004 vaccine neutralized H5 virus or mediated ADCC with
122 matched and mismatched H5 HAs. The vaccine elicited antibodies that neutralized clade
123 1 virus (**Extended Data Fig. 4a-c**) with larger fold-change titer increases in children
124 (**Extended Data Fig. 4d**). The clade 1 vaccine antigen also elicited clade 2.3.4.4b
125 neutralizing antibodies in some participants, but this was more sporadic (**Extended Data**

126 **Fig. 4e-h**). ADCC activity against the clade 1 and clade 2.3.4.4b H5N1 viruses was high
127 in serum from older individuals prior to vaccination (**Extended Data Fig. 4i and 4m**) and
128 increased in younger individuals following vaccination (**Extended Data Fig. 4j-k and 4n-**
129 **o**), with the largest ADCC titer fold change in children following vaccination (**Extended**
130 **Data Fig. 4l and 4p**).

131 Finally, we directly compared antibody titers from our healthy donors (**Fig. 1**) with
132 pre-vaccination titers from adults from the H5 vaccine trials (**Fig. 2**). Since these
133 samples were collected 12 years apart (2005 versus 2017), we were able to determine if
134 H5 antibody levels were more closely associated with birth year or age (**Fig. 3a-b**).
135 Consistent with immune imprinting, antibody levels were similar across these datasets
136 when plotted as a function of birth year (**Fig. 3a**) but different when plotted as a function
137 of age (**Fig. 3b**). Using two different statistical approaches, we found that titers to full
138 length H5 proteins from clade 1 and clade 2.3.4.4b (but not to the H5 stalk) had stronger
139 statistical associations with year of birth and group 1 imprinting probability than with age
140 (**Tables S2 and S3**). Antibody levels were less strongly associated with H1N1 imprinting
141 than with group 1 imprinting, suggesting that initial infections with H1N1 or H2N2 prime
142 antibody responses against clade 1 and clade 2.3.4.4b H5 proteins. Taken together,
143 these analyses corroborate the role of imprinting with group 1 viruses in shaping
144 antibody levels to H5N1 in humans.

145 Further studies need to be completed to determine if strong immunological
146 imprinting is solely a byproduct of initial influenza virus encounters or if multiple
147 exposures during childhood are required to prime robust memory B cell responses. Our
148 previous studies suggest that heterosubtypic influenza virus infections in ferrets and
149 humans boost HA stalk responses against the originally infecting viral subtype²⁷.
150 Longitudinal cohort studies, in which infections and vaccinations are tracked carefully
151 from birth, are required to better understand how childhood exposures impact the

152 generation of influenza virus antibodies later in life. In our experiments, younger
153 individuals possessed lower levels of H5-reactive antibodies prior to vaccination, and it is
154 likely that many of the younger children in our study had not yet been exposed to group
155 1 viruses at the time of sample collection.

156 Our study has limitations. For our vaccination studies, we analyzed serum
157 samples from 3 separate clinical studies to compare antibody responses elicited in
158 individuals with diverse birth years. The same vaccine formulation, dose, and
159 vaccination schedule were used in all 3 clinical studies, so it is unlikely that the observed
160 differences were due to clinical study differences. We only compared antibody
161 responses elicited by unadjuvanted vaccines in our studies. Khurana and colleagues
162 recently reported that adjuvanted clade 1 H5N1 vaccines elicit antibodies with high
163 reactivity to clade 2.3.4.4b H5N1 viruses²⁵, and it will be important for future studies to
164 evaluate if there are birth year-related differences in responses to adjuvanted vaccines.
165 We only evaluated antibody responses to HA, and additional studies should be
166 completed to determine if humans possess cross-reactive antibodies against the
167 neuraminidase protein of H5N1. Finally, all our vaccine studies were based on clade 1
168 H5N1 antigens, and future studies should evaluate responses to other vaccine antigens
169 based on more contemporary H5N1 strains.

170 Based on our studies and the observation that H5N1 viruses have typically
171 caused more disease in younger individuals^{15,16}, it is possible that older individuals
172 would be partially protected in the event of an H5N1 pandemic. Younger individuals who
173 have fewer group 1 influenza virus exposures would likely benefit more from an H5N1
174 vaccine, even a mismatch stockpiled vaccine²⁸. It will be important to continue to test
175 new updated vaccine antigens in individuals with diverse birth years, including children.
176 It will also be important to closely monitor clade 2.3.4.4b H5N1 virus circulating in wild

177 and domestic animals, as well as spillover infections of humans, so that we can continue
178 to evaluate the pandemic risk of these viruses.

179

180 **Acknowledgments**

181 We thank the Penn Medicine BioBank as a resource for obtaining serum from humans
182 with different birth years. We thank NIAID and the VTEU clinical study teams from DMID
183 04-063, DMID 04-076, and DMID04-0077 for providing sera samples from clinical
184 studies. This project was funded in part with Federal funds from the National Institute of
185 Allergy and Infectious Diseases, National Institutes of Health, Department of Health and
186 Human Services, under Contract Nos. 75N93021C00015 (S.E.H. and S.C.) and grant
187 numbers R01AI08686 (S.E.H.). S.E.H. holds an Investigators in the Pathogenesis of
188 Infectious Disease Awards from the Burroughs Wellcome Fund.

189

190 **Author Contributions Statement**

191 S.E.H., T.A.G., J.L., S.H.L., G.S., C.F., and J.J.S.S. designed the experiments. T.A.G.,
192 J.L., S.H.L., G.S., J.J.S.S., G.H., C.F., R.K.A., N.Y., J.O., K.A.H., and T.E. completed
193 experiments and analyzed data. K.K., M.C.V., and S.Co. performed modeling studies.
194 S.E.H. wrote the manuscript and all authors contributed to editing the manuscript. D.S.,
195 S.Ch., S.Co., and S.E.H. supervised experiments and data analyses. S.E.H. obtained
196 funding for the study.

197

198 **Competing Interests Statement**

199 S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as
200 a vaccine platform. S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen,
201 Novavax, and Merck. T.A.G. was an employee of the University of Pennsylvania when the

202 work was completed and is now an employee of GSK. The authors declare no other
203 competing interests.
204

205 **Figure Legends**

206 **Fig. 1. Group 1 immune imprinting primes robust H5-reactive antibody responses.**

207 (a) Group 1 (blue) and group 2 (red) influenza viruses have circulated at distinct times
208 since 1918. Sera samples were collected from healthy donors (n=121) at the Hospital of
209 the University of Pennsylvania in 2017 and we quantified IgG binding in ELISA to
210 'headless' A/California/4/2009 H1 stalk (b), 'headless' A/Vietnam/1203/2004 H5 stalk (c),
211 'headless' A/Finland/486/2004 H3 stalk (d), A/Shanghai/02/2013 H7 stalk (e), a clade 1
212 A/Vietnam/1203/2004 full length H5 HA (f) and a clade 2.3.4.4b A/Pheasant/New
213 York/22-009066-011/2022 full length H5 HA (g). (b-g) Vertical dashed lines mark years
214 of the 1957 H2N2 and 1968 H3N2 pandemics and 1977 reemergence of H1N1. Each
215 circle represents a geometric mean antibody titer in serum from a single donor from two
216 independent replicates, and the trend lines are locally estimated scatterplot smoothing
217 (LOESS) curves (smoothing parameter = 0.4, degree = 2) with 95% confidence intervals.

218

219 **Fig. 2. H5N1 vaccination elicits strong H5 stalk-reactive antibodies in children.**

220 Sera samples were obtained from participants (n=100) before (day 0) and 28 days after
221 receiving a first and second dose of an unadjuvanted A/Vietnam/1203/2004 H5N1
222 vaccine in 2005-2006. We quantified IgG binding to a 'headless' A/Vietnam/1203/2004
223 H5 stalk (a-c), and we calculated titer fold change by dividing day 28 post-boost titers by
224 day 0 titers (d). We also measured antibody binding and fold change to clade 1
225 A/Vietnam/1203/2004 full length H5 (e-h) and clade 2.3.4.4b A/Pheasant/New York/22-
226 009066-011/2022 full length H5 (i-l). Vertical dashed lines mark years of the 1957 H2N2
227 and 1968 H3N2 pandemics and 1977 reemergence of H1N1. Each circle represents a
228 geometric mean antibody titer in serum from a single donor from two independent
229 replicates. Samples from adults are grey and children are blue. Trend lines are locally

230 estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.4, degree =
231 2) with 95% confidence intervals, fitted to adult samples.

232

233 **Fig. 3. H5-rective antibody levels correlate better with birth year compared to age.**

234 Antibody titers in samples collected in 2005 (yellow) and 2017 (blue) against H5 stalk,
235 clade 1 A/Vietnam/1203/2004 full length H5, and clade 2.3.4.4b A/Pheasant/New
236 York/22-009066-011/2022 full length H5 are shown as a function of birth year (**a**) and
237 age (**b**). Vertical dashed lines mark years of the 1957 H2N2 and 1968 H3N2 pandemics
238 and 1977 reemergence of H1N1 (**a**). Each circle represents a geometric mean antibody
239 titer in serum from a single donor from two independent replicates. Trend lines are
240 locally estimated scatterplot smoothing (LOESS) curves (smoothing parameter = 0.65,
241 degree = 2) with 95% confidence intervals, fitted to adult samples.

242

243

244

245 References

- 246 1. Lewis, N.S., *et al.* Emergence and spread of novel H5N8, H5N5 and H5N1 clade
247 2.3.4.4 highly pathogenic avian influenza in 2020. *Emerging Microbes &*
248 *Infections* **10**, 148-151 (2021).
- 249 2. Caliendo, V., *et al.* Transatlantic spread of highly pathogenic avian influenza
250 H5N1 by wild birds from Europe to North America in 2021. *Sci Rep* **12**, 11729
251 (2022).
- 252 3. King, J., *et al.* Highly pathogenic avian influenza virus incursions of subtype
253 H5N8, H5N5, H5N1, H5N4, and H5N3 in Germany during 2020-21. *Virus*
254 *Evolution* **8**(2022).
- 255 4. Adlhoch, C., *et al.* Avian influenza overview December 2022 - March 2023. *Efsa j*
256 **21**, e07917 (2023).
- 257 5. Rijks, J.M., *et al.* Highly Pathogenic Avian Influenza A(H5N1) Virus in Wild Red
258 Foxes, the Netherlands, 2021. *Emerg Infect Dis* **27**, 2960-2962 (2021).
- 259 6. Puryear, W., *et al.* Outbreak of Highly Pathogenic Avian Influenza H5N1 in New
260 England Seals. *bioRxiv*, 2022.2007.2029.501155 (2022).
- 261 7. Pyankova, O.G., *et al.* Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic
262 avian influenza virus, from a worker during an outbreak on a poultry farm,
263 Russia, December 2020. *Euro Surveill* **26**(2021).
- 264 8. Agüero, M., *et al.* Highly pathogenic avian influenza A(H5N1) virus infection in
265 farmed minks, Spain, October 2022. *Euro Surveill* **28**(2023).
- 266 9. Nguyen, T.Q., Hutter, C., Markin, A., Thomas, M., Lantz, K., Killian, M.L., Janzen,
267 G.M., Vijendran, S., Wagle, S., Inderski, B., Magstadt, D.R., Li, G., Diel, D.G.,
268 Frye, E.A., Dmitrov, K.M., Swinford, A.K., Thompson, A.C., Snevik, K.R., Suarez,
269 D.L., Spackman, E., Lakin, S.M., Ahola, S.C., Johnson, K.R., Baker, A.L., Robbe-
270 Austerman, S., Torchetti, M.K., Anderson, T.K. Emergence and interstate spread
271 of highly pathogenic avian influenza A(H5N1) in dairy cattle. *bioRxiv*
272 <https://doi.org/10.1101/2024.05.01.591751>(2024).
- 273 10. Burrough, E.R., *et al.* Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b
274 Virus Infection in Domestic Dairy Cattle and Cats, United States, 2024. *Emerg*
275 *Infect Dis* **30**, 1335-1343 (2024).
- 276 11. Santos, J.J.S., *et al.* Bovine H5N1 influenza virus binds poorly to human-type
277 sialic acid receptors. *bioRxiv* (2024).
- 278 12. Chopra, P., *et al.* Receptor Binding Specificity of a Bovine A(H5N1) Influenza
279 Virus. *bioRxiv* (2024).
- 280 13. Neumann, G. & Kawaoka, Y. Highly pathogenic H5N1 avian influenza virus
281 outbreak in cattle: the knowns and unknowns. *Nat Rev Microbiol* **22**, 525-526
282 (2024).
- 283 14. Moratorio, G., *et al.* H5N1 influenza: Urgent questions and directions. *Cell* **187**,
284 4546-4548 (2024).
- 285 15. Qin, Y., *et al.* Differences in the Epidemiology of Human Cases of Avian
286 Influenza A(H7N9) and A(H5N1) Viruses Infection. *Clinical infectious diseases :*
287 *an official publication of the Infectious Diseases Society of America* **61**, 563-571
288 (2015).
- 289 16. Cowling, B.J., *et al.* Comparative epidemiology of human infections with avian
290 influenza A H7N9 and H5N1 viruses in China: a population-based study of
291 laboratory-confirmed cases. *Lancet* **382**, 129-137 (2013).
- 292 17. Krammer, F., *et al.* Influenza. *Nat Rev Dis Primers* **4**, 3 (2018).


- 293 18. Gostic, K.M., Ambrose, M., Worobey, M. & Lloyd-Smith, J.O. Potent protection
294 against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting.
295 *Science* **354**, 722-726 (2016).
- 296 19. Nachbagauer, R., *et al.* Age Dependence and Isotype Specificity of Influenza
297 Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. *mBio* **7**, e01996-
298 01915 (2016).
- 299 20. Yassine, H.M., *et al.* Use of Hemagglutinin Stem Probes Demonstrate
300 Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.
301 *Scientific reports* **8**, 8628 (2018).
- 302 21. Sanchez-de Prada, L., *et al.* Group 1 and group 2 hemagglutinin stalk antibody
303 response according to age. *Frontiers in immunology* **14**, 1194073 (2023).
- 304 22. Ledgerwood, J.E., *et al.* DNA priming and influenza vaccine immunogenicity: two
305 phase 1 open label randomised clinical trials. *Lancet Infect Dis* **11**, 916-924
306 (2011).
- 307 23. Ellebedy, A.H., *et al.* Induction of broadly cross-reactive antibody responses to
308 the influenza HA stem region following H5N1 vaccination in humans.
309 *Proceedings of the National Academy of Sciences of the United States of*
310 *America* **111**, 13133-13138 (2014).
- 311 24. Treanor, J.J., Campbell, J.D., Zangwill, K.M., Rowe, T. & Wolff, M. Safety and
312 immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *The New*
313 *England journal of medicine* **354**, 1343-1351 (2006).
- 314 25. Khurana, S., *et al.* Licensed H5N1 vaccines generate cross-neutralizing
315 antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. *Nature*
316 *medicine* (2024).
- 317 26. DiLillo, D.J., Palese, P., Wilson, P.C. & Ravetch, J.V. Broadly neutralizing anti-
318 influenza antibodies require Fc receptor engagement for in vivo protection. *The*
319 *Journal of clinical investigation* **126**, 605-610 (2016).
- 320 27. Arevalo, C.P., *et al.* Original antigenic sin priming of influenza virus
321 hemagglutinin stalk antibodies. *Proceedings of the National Academy of*
322 *Sciences of the United States of America* **117**, 17221-17227 (2020).
- 323 28. Webby, R.J. The practical longevity of stockpiled A(H5N1) influenza vaccine.
324 *Nature medicine* (2024).
- 325

326

327


Fig. 1

a




b

H1 Stalk




c

H5 Stalk




d

H3 Stalk




e

H7 Stalk



f

Clade 1 H5



g

Clade 2.3.4.4b H5






Fig. 2

H5 stalk binding antibody



Clade 1 H5 binding antibody



Clade 2.3.4.4b H5 binding antibody





Fig. 3**a****b**